{"id":"capecitabine-irinotecan","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL3989514","moleculeType":"Small molecule","molecularWeight":"677.19"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Capecitabine is converted into 5-fluorouracil, which is then phosphorylated into its active form, 5-fluorodeoxyuridylate. This inhibits thymidylate synthase, leading to DNA damage and cell death. Irinotecan, on the other hand, inhibits topoisomerase I, preventing DNA replication and transcription.","oneSentence":"Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:24.842Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07474103","phase":"NA","title":"SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-11-30","conditions":"Rectal Cancer, Adenocarcinoma","enrollment":49},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT04215731","phase":"PHASE3","title":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2020-03-27","conditions":"Rectal Cancer","enrollment":582},{"nctId":"NCT07446387","phase":"PHASE2","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":70},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT07395063","phase":"PHASE2","title":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT05062317","phase":"PHASE2","title":"ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-26","conditions":"Liver Metastases","enrollment":120},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT06958328","phase":"PHASE3","title":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-08-21","conditions":"Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":356},{"nctId":"NCT03875781","phase":"PHASE3","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-06-05","conditions":"Rectal Cancer, Advanced Cancer","enrollment":540},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07056777","phase":"PHASE1, PHASE2","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Zhejiang Doer Biologics Co., Ltd.","startDate":"2025-03-25","conditions":"Gastrointestinal Cancer","enrollment":186},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07281157","phase":"PHASE2","title":"Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11-01","conditions":"Advanced Colorectal Cancer","enrollment":30},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT06065371","phase":"PHASE1","title":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2024-11-20","conditions":"Gastrointestinal Cancer","enrollment":20},{"nctId":"NCT02314182","phase":"PHASE3","title":"GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-11-20","conditions":"Rectal Adenocarcinoma","enrollment":5},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT07277842","phase":"PHASE3","title":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-29","conditions":"Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)","enrollment":382},{"nctId":"NCT05358704","phase":"PHASE2","title":"Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer","status":"SUSPENDED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-05-13","conditions":"Cancer of Rectum","enrollment":38},{"nctId":"NCT04753879","phase":"PHASE2","title":"Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-09-29","conditions":"Metastatic Pancreatic Cancer","enrollment":38},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT05610163","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-12-08","conditions":"Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":783},{"nctId":"NCT05990543","phase":"PHASE1, PHASE2","title":"Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-01-29","conditions":"Recurrent or Metastatic Colorectal Cancer","enrollment":59},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT02605265","phase":"PHASE3","title":"Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-10","conditions":"Locally Advanced Rectal Cancer","enrollment":356},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT06095141","phase":"PHASE2, PHASE3","title":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Pancreatic Adenocarcinoma, Homologous Recombination Deficiency","enrollment":30},{"nctId":"NCT06865521","phase":"NA","title":"Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"West China Hospital","startDate":"2025-02-21","conditions":"Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila","enrollment":22},{"nctId":"NCT06813976","phase":"PHASE3","title":"PRODIGE 98 : Randomized, Multicenter Phase 3 Trial of Adjuvant Chemotherapy With Modified FOLFIRINOX Versus Capecitabine or Gemcitabine in Patients With Resected Ampullary Adenocarcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-07-02","conditions":"Ampullary Adenocarcinoma","enrollment":294},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT07051785","phase":"PHASE2","title":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liu Huang","startDate":"2025-07-07","conditions":"Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT03764553","phase":"PHASE2","title":"Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-05-01","conditions":"Esophageal Cancer","enrollment":320},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT05929885","phase":"PHASE2","title":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2023-08-30","conditions":"Metastatic Pancreatic Cancer","enrollment":50},{"nctId":"NCT04736472","phase":"NA","title":"Implementing Pharmacogenetic Testing in Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-03-26","conditions":"Gastrointestinal Cancer","enrollment":552},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06973343","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-05","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT06963502","phase":"PHASE1","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-30","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer","enrollment":762},{"nctId":"NCT06622057","phase":"PHASE3","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2025-07-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":195},{"nctId":"NCT02934529","phase":"PHASE3","title":"Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2015-03","conditions":"Metastatic Colorectal Cancer","enrollment":673},{"nctId":"NCT06928584","phase":"PHASE2","title":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-10","conditions":"Locally Recurrent Rectal Cancer","enrollment":221},{"nctId":"NCT06621563","phase":"PHASE1","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2024-12-14","conditions":"Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":780},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT05646511","phase":"PHASE3","title":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-11-21","conditions":"Locally Advanced Rectal Cancer","enrollment":608},{"nctId":"NCT05379790","phase":"PHASE1","title":"Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-05-25","conditions":"Gastric Cancer, Peritoneal Metastases","enrollment":20},{"nctId":"NCT06899477","phase":"PHASE3","title":"Pre-Operative Treatment in REseCTable COlon CanceR","status":"NOT_YET_RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2025-04","conditions":"Colo-rectal Cancer, Colon Cancer, Colon Carcinoma","enrollment":714},{"nctId":"NCT06894797","phase":"NA","title":"Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-04-01","conditions":"Locally Advanced Rectal Cancer","enrollment":68},{"nctId":"NCT06417476","phase":"PHASE2","title":"Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer","status":"RECRUITING","sponsor":"Pei-Rong Ding","startDate":"2022-12-12","conditions":"Rectal Neoplasms","enrollment":66},{"nctId":"NCT06210971","phase":"PHASE2","title":"Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-02-01","conditions":"Rectal Cancer","enrollment":60},{"nctId":"NCT06867146","phase":"NA","title":"MRD in PAAD Adjuvant Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-10-15","conditions":"The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer","enrollment":60},{"nctId":"NCT03387592","phase":"PHASE2","title":"CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2017-03-06","conditions":"Neuroendocrine Carcinoma","enrollment":53},{"nctId":"NCT04380337","phase":"PHASE2","title":"Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-05-21","conditions":"Rectal Cancer","enrollment":38},{"nctId":"NCT06578052","phase":"NA","title":"Irinotecan Liposome in Combination With Capecitabine","status":"RECRUITING","sponsor":"Junjie Hang","startDate":"2024-08-28","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT02485834","phase":"PHASE2","title":"FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-11-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer","enrollment":5},{"nctId":"NCT06776757","phase":"PHASE1, PHASE2","title":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2023-12-25","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT01821612","phase":"EARLY_PHASE1","title":"Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2013-05-29","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer","enrollment":23},{"nctId":"NCT03535727","phase":"PHASE1, PHASE2","title":"A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-06-21","conditions":"Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular","enrollment":48},{"nctId":"NCT03974854","phase":"PHASE2","title":"Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2019-07-08","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":25},{"nctId":"NCT06751394","phase":"PHASE2","title":"Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-01","conditions":"Recurrent Rectal Cancer","enrollment":44},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT06405490","phase":"PHASE2","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-17","conditions":"Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin","enrollment":30},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT05546411","phase":"PHASE2","title":"A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer","status":"TERMINATED","sponsor":"Kimberly Perez, MD","startDate":"2023-01-06","conditions":"Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":8},{"nctId":"NCT01531595","phase":"PHASE2","title":"Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pia Osterlund","startDate":"2012-02","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06242418","phase":"PHASE2","title":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-03-25","conditions":"Colon Cancer","enrollment":60},{"nctId":"NCT05314998","phase":"PHASE3","title":"Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature","status":"NOT_YET_RECRUITING","sponsor":"John Neoptolemos","startDate":"2025-01-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":394},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT06405139","phase":"PHASE2","title":"Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-01","conditions":"Colorectal Cancer","enrollment":36},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT06699459","phase":"PHASE2","title":"Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-11-14","conditions":"Biliary Tract Carcinoma","enrollment":76},{"nctId":"NCT06389760","phase":"PHASE2","title":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-10-18","conditions":"Pancreatic Cancer","enrollment":57},{"nctId":"NCT06665087","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":110},{"nctId":"NCT06652412","phase":"PHASE2","title":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11","conditions":"Colon Cancer, Rectal Cancer","enrollment":124},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT04725994","phase":"PHASE1, PHASE2","title":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Idience Co., Ltd.","startDate":"2021-06-28","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT03879109","phase":"PHASE3","title":"Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2019-07-08","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT02514278","phase":"PHASE3","title":"Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-01-28","conditions":"Rectal Cancer","enrollment":218},{"nctId":"NCT06513221","phase":"PHASE2","title":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-25","conditions":"Metastatic Colorectal Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":90,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"capecitabine-irinotecan","genericName":"capecitabine-irinotecan","companyName":"Dutch Colorectal Cancer Group","companyId":"dutch-colorectal-cancer-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}